Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Good point. The obvious conclusion is Gilead understands Remdesivir's deficiencies as a Covid19 drug are even more obvious now that Regeneron's "dual antibody" drug is out and they want Remdesivir to maintain some market share as a Covid19 drug.

To be competitive Gilead believes a combination with another drug may allow Remdesivir to stay in the game. Combining antivirals with different mechanisms of action makes sense.

That does not rule out a combination with Brilacidin especially since the in vitro studies suggest Remdesivir and Brilacidin are synergistic against Covid19.

Brilacidin is not an option at this stage because it has not completed human trials. Hopefully Brilacidin will be successful in human trials and be given an EUA. It would then join the other drugs which are operating under EUAs,Remdesivir, Convalescent plasma and Regeneron's antibody drug.

No drug has been approved as a treatment for Covid19 to date.

IPIX needs to get the studies done!

GLTA Farrell